3.4 Antigen-antibody interactions

Antigen-Antibody Interaction Fundamentals

Antigen-antibody interactions are the molecular basis of adaptive immune responses. These interactions depend entirely on non-covalent bonds, and their combined strength determines how effectively an antibody can recognize and neutralize a specific target. This section covers the bond types involved, how specificity works, and how these interactions are exploited in immunoassays and clinical applications.

Types of antigen-antibody bonds

All antigen-antibody binding is non-covalent. No single bond type is strong enough on its own to hold the complex together. Instead, many weak bonds act together across the contact surface between the antibody's paratope and the antigen's epitope, producing a stable interaction.

The four main bond types:

• Electrostatic (ionic) interactions form between oppositely charged groups (e.g., $-NH_3^+$ and $-COO^-$). These are the strongest of the four non-covalent bond types and are highly distance-dependent.
• Hydrogen bonds form when a hydrogen atom bonded to an electronegative atom (like O or N) interacts with another electronegative atom. Individually weak, but dozens of hydrogen bonds across a binding interface add up to a significant contribution.
• Hydrophobic interactions occur when non-polar side chains on both the antibody and antigen are excluded from water and cluster together. These help stabilize the overall complex geometry.
• Van der Waals forces are the weakest individually. They arise from transient dipoles between atoms in very close proximity. Their contribution becomes meaningful only when the antibody and antigen surfaces are highly complementary, maximizing the number of close atomic contacts.

Relative bond strengths (strongest to weakest):

1. Electrostatic interactions
2. Hydrogen bonds
3. Hydrophobic interactions
4. Van der Waals forces

The overall binding strength of a single antibody-antigen contact is called affinity, while avidity refers to the total binding strength when multiple binding sites engage simultaneously (e.g., an IgM pentamer binding a multivalent antigen). Avidity can be much greater than affinity alone.

Antibody specificity and cross-reactivity

Specificity refers to an antibody's ability to bind one particular epitope and not others. This is determined by the shape and charge distribution of the complementarity-determining regions (CDRs), the hypervariable loops within the variable domains of the heavy and light chains. The better the fit between CDRs and epitope, the more non-covalent bonds form, and the higher the affinity.

Cross-reactivity occurs when an antibody binds to more than one antigen. This happens because different antigens can share structurally similar epitopes. Cross-reactivity is not always a problem; it can broaden immune protection. But it can also cause diagnostic false positives or contribute to autoimmune pathology.

Factors that influence specificity and cross-reactivity:

• Structural similarity between antigens: Proteins with conserved regions (e.g., hemoglobin variants across species) may share epitopes that a single antibody recognizes.
• Flexibility of the binding site: Some antibodies have CDR loops that can adopt slightly different conformations, allowing them to accommodate more than one epitope shape.
• Environmental conditions: Changes in pH, temperature, or ionic strength can alter the charge distribution or conformation of both antibody and antigen, shifting binding behavior.

Immunoassays and Applications

Immunoassays exploit the specificity of antigen-antibody interactions to detect and quantify molecules in biological samples. They are central tools in diagnostics, research, and quality control.

Principles of immunoassays

Enzyme-Linked Immunosorbent Assay (ELISA) uses enzyme-conjugated antibodies to generate a measurable signal (usually a color change) when the target antigen or antibody is present.

Four main ELISA formats:

• Direct ELISA: Antigen is bound to the plate, and an enzyme-linked primary antibody detects it. Simple but less sensitive.
• Indirect ELISA: Antigen is bound to the plate, a primary antibody binds it, and then an enzyme-linked secondary antibody binds the primary. More sensitive due to signal amplification.
• Sandwich ELISA: A capture antibody on the plate binds the antigen, then a second enzyme-linked detection antibody binds a different epitope on the same antigen. Highly specific because two antibodies must recognize the target.
• Competitive ELISA: Sample antigen competes with labeled antigen for antibody binding. Signal decreases as sample antigen concentration increases.

ELISA applications include HIV screening, food allergen detection, and hormone level measurement (e.g., hCG in pregnancy tests).

Western blot combines protein separation with antibody-based detection. It's used when you need to confirm both the presence and the molecular weight of a target protein.

Western blot steps:

1. Sample preparation: Proteins are extracted and denatured (usually with SDS).

2. Gel electrophoresis: Proteins are separated by molecular weight through SDS-PAGE.

3. Transfer to membrane: Separated proteins are transferred (blotted) onto a nitrocellulose or PVDF membrane.

4. Blocking: The membrane is incubated with a blocking agent (e.g., BSA or non-fat milk) to prevent non-specific antibody binding.

5. Antibody incubation: A primary antibody specific to the target protein is applied, followed by an enzyme- or fluorophore-linked secondary antibody.

6. Detection: The enzyme substrate produces a visible band, or fluorescence is measured, at the position corresponding to the target protein's molecular weight.

Western blot applications include HIV confirmation testing (following a positive ELISA screen), Lyme disease diagnosis, and general protein research.

Common features across immunoassays:

• Labeled antibodies or antigens serve as the detection mechanism (labels can be enzymatic, fluorescent, or radioactive)
• Specificity comes from the antigen-antibody interaction itself
• Signal amplification strategies (e.g., enzyme-substrate reactions where one enzyme molecule generates many detectable product molecules) increase sensitivity

Applications in vaccines and immunotherapies

Antigen-antibody interactions are not just studied in the lab. They're the basis for several major clinical strategies.

• Vaccine development relies on identifying protective antigens that elicit strong, specific antibody responses. The goal is to generate memory B cells that produce high-affinity antibodies upon re-exposure.
• Monoclonal antibody therapies use lab-produced antibodies that target specific antigens. Examples include trastuzumab (Herceptin) for HER2-positive breast cancer and adalimumab (Humira) for autoimmune conditions like rheumatoid arthritis.
• Passive immunization provides immediate but temporary protection by administering pre-formed antibodies. Rabies post-exposure prophylaxis uses rabies immune globulin for this purpose.
• Antibody engineering modifies antibody structure to improve clinical performance. Chimeric antibodies combine mouse variable regions with human constant regions. Humanized antibodies go further, grafting only the CDRs from a mouse antibody onto a human framework. Both approaches reduce immunogenicity (the risk that the patient's immune system attacks the therapeutic antibody).
• Diagnostic rapid tests use antigen-antibody interactions in lateral flow format for point-of-care results. Pregnancy tests detect hCG, and COVID-19 antigen tests detect viral nucleocapsid protein, both within minutes.